The Department of Health (DOH) will look into the reason why the government bought the now-controversial vaccine, Dengvaxia, for P1,000 per dose instead of P600, Health Secretary Francisco III said on Wednesday.
This after lawmakers during the House committee on good government and public accountability on the botched dengue immunization program found that the cost-effectiveness study commissioned by Sanofi Pasteur recommended the vaccine to be bought for $21 or P1,000.
鈥淣agulat talaga ako kasi hindi ko alam 鈥榶on e (I was really surprised because I do not know those details.) I was never privy to that information, if there was any. First time I鈥檝e heard it this afternoon,鈥 Duque told reporters after the hearing.
鈥淪o we鈥檒l have to validate and understand the reason for the price differential kasi malaki rin yung (there鈥檚 a huge gap in the) price differential. So I don鈥檛 know the economic factors that were introduced in the study that did the pricing,鈥 he added.
The study was led by Dr. Hilton Lam, a member of the DOH鈥檚 Formulary Executive Committee. Lam admitted that he was paid by Sanofi Pasteur for P300,000 for undertaking the research. He said the company paid the team about P3 million for the study.
This did not sit well with the lawmakers, who said it was inappropriate for him to undertake the study being a member of the FEC, the DOH body that approves the medicines to be included in the National Formulary, or the list of drugs the government can buy and use.
Lam told lawmakers that the vaccine鈥檚 threshold price is at $13 per dose (P600) while the 鈥渟ocietal price鈥 is at $21 (P1,000) per dose. He said the latter amount included 鈥減roductivity losses鈥 or the accounting of one鈥檚 future income if he dies or the loss of income if someone鈥檚 parents die.
Albay Rep. Joey Salceda took swipe at Lam鈥檚 explanation, saying he 鈥渨ould probably buy the drug鈥 but not Lam鈥檚 logic.